Core Viewpoint - Rosen Law Firm is reminding investors who purchased Iovance Biotherapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, and highlights the potential for compensation without out-of-pocket costs through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought Iovance securities between May 9, 2024, and May 8, 2025, may be eligible to join a class action lawsuit [1][2]. - The lawsuit alleges that Iovance made false and misleading statements regarding the effectiveness of its sales team and new Authorized Treatment Centers (ATCs), which resulted in higher costs and lower revenue due to patient drop-offs and delays in treatment initiation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, noting that many firms may not have the necessary experience or resources [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019, and has been recognized for its success in securities class action settlements [4].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial guidance and cost trends related to Medicaid redetermination processes during the specified Class Period [1][4][5]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, Indiana, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Lawsuit Details - The lawsuit claims that Elevance misled investors by stating they were effectively monitoring cost trends and that premium rates negotiated with states were sufficient to cover rising Medicaid expenses [4]. - It is alleged that the company did not adequately reflect the impact of Medicaid redeterminations, which resulted in a higher utilization of Medicaid members who remained eligible, as those removed were generally healthier [5]. Investor Information - Investors who purchased Elevance securities during the Class Period have until July 11, 2025, to seek appointment as lead plaintiff representatives [2].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in its stock price following the termination of its partnership with Novo Nordisk [2][3]. Group 1: Company Actions and Events - On April 29, 2025, Hims announced a collaboration with Novo Nordisk to sell a bundled offering of Wegovy on its platform [2]. - On June 23, 2025, Novo Nordisk terminated its partnership with Hims, citing deceptive promotion and safety risks associated with Hims' products [2]. - Following the termination announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [2]. Group 2: Lawsuit Details - The class action lawsuit alleges that Hims made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specific allegations include Hims' engagement in deceptive practices regarding the sale of knockoff Wegovy versions and the risk of partnership termination with Novo Nordisk [3]. - The lawsuit claims that Hims' positive statements about its business lacked a reasonable basis due to these undisclosed risks [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who purchased West Pharmaceutical common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 7, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5] - Specific claims include that West was experiencing significant destocking in its high-margin products, contrary to its public statements, and that the SmartDose device was negatively impacting profit margins due to operational inefficiencies [5] - The lawsuit asserts that these misleading statements led to investor damages when the true situation was revealed [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in terms of settlements [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in representing investor interests [4]

Core Viewpoint - The article discusses a class action lawsuit against Vestis Corporation due to significant stock price decline following disappointing financial results and misleading statements made by the company regarding its growth and revenue guidance [2][3]. Group 1: Financial Performance - On May 7, 2025, Vestis reported its second quarter fiscal 2025 financial results, revising its growth and revenue guidance for 2025, which fell significantly below market expectations [2]. - The company attributed the poor results to "lost business in excess of new business" and "lower adds over stops," indicating a decline in revenue from existing customers [2]. Group 2: Stock Price Impact - Following the announcement of the disappointing financial results, Vestis's stock price dropped by $3.27, or 37.5%, closing at $5.44 per share on May 7, 2025, resulting in losses for investors [2]. Group 3: Lawsuit Details - The class action lawsuit alleges that during the Class Period, Vestis made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Specifically, the lawsuit claims that the company was not equipped to achieve its growth guidance, leading to a significant revenue decline from existing customers, which rendered the positive statements misleading [3]. Group 4: Legal Action - Investors who purchased Vestis securities during the Class Period have until August 8, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Core Viewpoint - The article discusses a class action lawsuit against Vestis Corporation due to significant stock price decline following disappointing financial results and misleading statements made by the company regarding its growth and revenue guidance [3][4]. Group 1: Financial Performance - On May 7, 2025, Vestis reported its second quarter fiscal 2025 financial results, revising its growth and revenue guidance for 2025, which fell significantly below market expectations [3]. - The company attributed the poor results to "lost business in excess of new business" and "lower adds over stops," indicating a decline in revenue from existing customers [3]. Group 2: Stock Price Impact - Following the release of the disappointing financial results, Vestis's stock price dropped by $3.27, or 37.5%, closing at $5.44 per share on May 7, 2025, resulting in losses for investors [3]. Group 3: Lawsuit Details - The class action lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [4]. - Specifically, the lawsuit claims that the company was not equipped to achieve its growth guidance, leading to a significant revenue decline from existing customers, which rendered the defendants' positive statements misleading [4]. Group 4: Legal Actions - Investors who purchased Vestis securities during the Class Period have until August 8, 2025, to file a lead plaintiff motion in the ongoing lawsuit [5].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for alleged misrepresentation regarding its capital allocation priorities and dividend payouts following its acquisition of Dermavant [1][3][4]. Company Overview - Organon & Co. is a healthcare company focused on women's health, headquartered in Jersey City, NJ [2]. - In October 2024, Organon acquired Dermavant, a biopharmaceutical company, for $1.2 billion [2]. Lawsuit Details - The lawsuit claims that despite increasing debt from the Dermavant acquisition, Organon assured investors it would maintain its dividend as its "1 capital allocation priority" [3]. - Following the acquisition, Organon allegedly shifted its capital allocation focus to debt reduction, contrary to its previous assurances [3]. Dividend Changes - On May 1, 2025, Organon announced a significant reduction in its dividend payout from $0.28 per share to $0.02 per share, citing a reset of capital allocation priorities to prioritize deleveraging [4]. - This announcement led to a decline in Organon's stock price by $3.48 per share, approximately 27%, from $12.93 to $9.45 on the following day [4].

Core Viewpoint - Iovance Biotherapeutics, Inc. faces a class action lawsuit following a significant decline in its financial performance and revenue guidance, leading to a sharp drop in its stock price [1][2][3]. Financial Performance - For Q1 2025, Iovance reported total product revenue of $49.3 million, down from $73.7 million in the previous quarter, indicating a decline of approximately 33% [2]. - The company revised its full fiscal year 2025 revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [2]. Lawsuit Details - The class action lawsuit alleges that Iovance made materially false and misleading statements regarding its business operations and prospects during the class period [3]. - Specific allegations include delays in new Authorized Treatment Centers (ATCs) beginning patient treatments, inefficiencies in patient identification and selection, and resulting higher costs and lower revenues due to ATCs not keeping pace with manufactured products [3]. Legal Action - Investors who purchased Iovance securities during the class period have until July 14, 2025, to file a lead plaintiff motion in the class action lawsuit [1][4].

Core Viewpoint - Digimarc Corporation is facing a class action lawsuit due to significant declines in subscription revenue and annual recurring revenue, which were not disclosed to investors during the class period [2][3]. Financial Performance - On February 26, 2025, Digimarc reported a 10% drop in quarterly subscription revenue and a decrease in annual recurring revenue by approximately $2 million, primarily due to a $5.8 million decrease in ARR from a commercial contract expiration in June 2024 [2]. - Following the announcement, Digimarc's stock price fell by $11.65, or 43.1%, closing at $15.39 per share on February 27, 2025 [2]. Lawsuit Details - The class action complaint alleges that Digimarc's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include the failure to disclose that a major commercial partner would not renew a significant contract on the same terms, leading to renegotiation and adverse effects on subscription and annual recurring revenue [3]. Class Action Participation - Investors who purchased Digimarc securities during the class period can file a motion to be appointed as lead plaintiff by July 8, 2025 [4].

Core Viewpoint - The article discusses a class action lawsuit against NET Power Inc. due to significant delays and cost overruns related to its Project Permian, which has negatively impacted the company's stock price and investor confidence [1][6]. Financial Performance and Events - On November 14, 2023, NET Power announced a delay in its Project Permian, pushing the expected operational date from 2026 to between the second half of 2027 and the first half of 2028, citing global supply chain issues [2]. - Following this announcement, NET Power's stock price dropped by $2.47, or 18.5%, closing at $10.85 per share [3]. - On March 10, 2025, the company revealed that the cost estimate for Project Permian had risen significantly, with total installed costs now estimated between $1.7 billion and $2 billion, leading to another stock price decline of $2.18, or 31.5%, closing at $4.75 per share [4]. - On April 15, 2025, the departure of key executives resulted in a further stock price decrease of $0.13, or 5.8%, closing at $2.13 per share [5]. Lawsuit Details - The class action lawsuit alleges that NET Power made materially false and misleading statements regarding the project's timeline and costs, failing to disclose the likelihood of delays and increased expenses due to supply chain issues and other challenges [6]. - Investors who purchased NET Power securities during the class period (June 9, 2023, to March 7, 2025) are encouraged to file a lead plaintiff motion by June 17, 2025 [1][7].